PP
RXRX icon

PDS Planning’s Recursion Pharmaceuticals RXRX Stock Holding History

PDS Planning’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74.4K Buy
24,246
+10,558
+77% +$40.8K ﹤0.01% 552
2025
Q4 		$56K Hold
13,688
– – ﹤0.01% 545
2025
Q3 		$66.8K Buy
13,688
+1,240
+10% +$6.51K ﹤0.01% 533
2025
Q2 		$63K Sell
12,448
-640
-5% -$3.14K ﹤0.01% 508
2025
Q1 		$69.2K Buy
+13,088
New +$95.4K 0.01% 467

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

PDS Planning's RXRX Position: Q1 2026 in Review

PDS Planning increased its Recursion Pharmaceuticals (RXRX) stake by 77% in Q1 2026, buying an estimated $40.8K and bringing the position to 24,246 shares worth $74.4K. The position accounts for ﹤0.01% of the portfolio, ranked #552.

PDS Planning first reported a position in RXRX in Q1 2025 and has held it in 5 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • PDS Planning held 24,246 shares of Recursion Pharmaceuticals worth $74.4K as of Q1 2026.
  • PDS Planning bought 10,558 Recursion Pharmaceuticals shares in Q1 2026, an estimated $40.8K.
  • Recursion Pharmaceuticals made up ﹤0.01% of PDS Planning's portfolio in Q1 2026, its #552 holding.
  • PDS Planning first reported a position in Recursion Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on PDS Planning's 13F filing for Q1 2026, filed 22 Apr 2026.